BRTX
NASDAQ · Biotechnology
Biorestorative Therapies Inc
$0.30
+0.00 (+0.41%)
Financial Highlights (FY 2026)
Revenue
1.15M
Net Income
-25,837,300
Gross Margin
93.0%
Profit Margin
-2,239.3%
Rev Growth
+100.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 93.0% | 51.7% | 51.7% | 51.7% |
| Operating Margin | -2,881.6% | 24.8% | 20.5% | 20.6% |
| Profit Margin | -2,239.3% | 18.9% | 16.4% | 14.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.15M | 1.95M | 1.76M | 1.61M |
| Gross Profit | 1.07M | 1.01M | 911.0K | 830.3K |
| Operating Income | -33,215,857 | 484.6K | 360.9K | 330.2K |
| Net Income | -25,837,300 | 368.5K | 288.6K | 237.9K |
| Gross Margin | 93.0% | 51.7% | 51.7% | 51.7% |
| Operating Margin | -2,881.6% | 24.8% | 20.5% | 20.6% |
| Profit Margin | -2,239.3% | 18.9% | 16.4% | 14.8% |
| Rev Growth | +100.2% | +23.8% | +14.5% | +14.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 3.73M | 3.68M | 4.15M |
| Total Equity | — | 6.71M | 7.11M | 6.97M |
| D/E Ratio | — | 0.56 | 0.52 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -27,065,946 | 506.9K | 503.0K | 417.7K |
| Free Cash Flow | — | 427.1K | 335.8K | 390.7K |